UNITED STATES PATENT AND TRADEMARK OFFICE

_____

BEFORE THE PATENT TRIAL AND APPEAL BOARD

_____

DR. REDDY'S LABORATORIES, S.A. AND
DR. REDDY'S LABORATORIES, INC.,
Petitioners,

v.

EYE THERAPIES, LLC,
Patent Owner.

_____

Case No.: IPR2024-00563

U.S. Patent No.: 11,596,600

_____

PETITIONERS' FOURTH UPDATED EXHIBIT LIST

Exhibit List

IPR	Description
1001	U.S. Patent No. 11,833,245 (filed Jan. 30, 2023) (issued Dec. 5, 2023) ('245 patent).
1002	U.S. Patent No. 8,293,742 (filed July 27, 2009) (issued Oct. 23, 2012) ('742 Patent).
1003	*Slayback Pharma LLC v. Eye Therapies, LLC*, No. IPR2022-00142, Paper 77 (P.T.A.B. May 15, 2023).
1004	U.S. Patent No. 6,294,553 (filed Feb. 14, 2001) (issued Sep. 25, 2001) (Gil).
1005	Not Used
1006	Norden, R., "Effect of Prophylactic Brimonidine or Bleeding Complications and Flap Adherence after Laser in Situ Keratomileusis," *Journal of Refractive Surgery*, vol. 18, no. 4, July/ Aug. 2002 at 468–471.
1007	U.S. Patent 6,242,442 (filed Dec. 7, 1999) (issued June 5, 2001) (Dean).
1008	"Alphagan® (brimonidine tartrate ophthalmic solution) 0.2%." *in* PHYSICIANS' DESK REFERENCE 487 (52th ed., 1998).
1009	53 Fed. Reg. 43, 7076-7093 (Mar. 4, 1988).
1010	File Wrapper, U.S. Application for 17/585.395 filed January 26, 2022, downloaded from Patent Center.
1011	Not Used
1012	Declaration of Reza Dana MD, MSc, MPH
1013	Declaration of Paul A. Laskar, Ph.D.
1014	Declaration of John Galanis MD, FACS

1015	Not Used
1016	U.S. Provisional Application 61/207,481 filed February 12, 2009, downloaded from PAIR ('481 Provisional).
1017	Not Used
1018	Not Used
1019	Not Used
1020	Griffith, R. K., "Adrenergics and Adrenergic- Blocking Agents." *Burger's Medicinal Chemistry and Drug Discovery*, edited by Donald J. Abraham, 6th ed., vol. 6, John Wiley & Sons, Inc., New York, NY, 2003, pp. 2–37.
1021	David, R. "Brimonidine (Alphagan®): A Clinical Profile Four Years after Launch." *European Journal of Ophthalmology*, vol. 11, no. 2_suppl, 2001, pp. S72–S77.
1022	Wikberg-Matsson, A., and Simonsen, U. "Potent α_{2A}-Adrenoceptor–Mediated Vasoconstriction by Brimonidine in Porcine Ciliary Arteries." *Investigative Ophthalmology & Visual Science*, vol. 42, no. 9, Aug. 2001, pp. 2049–2055.
1023	Robin, A. L., and Burnstein, Y, "Selectivity of Site of Action and Systemic Effects of Topical Alpha Agonists." *Current Opinion in Ophthalmology*, vol. 9, no. 2, 1998, pp. 30–33.
1024	Lachkar, Y, and Dhanjill, S., "Effect of Brimonidine Tartrate on Ocular Hemodynamic Measurements." *Archives of Ophthalmology*, vol. 116, no. 12, Dec. 1998, pp. 1591–1594.
1025	Exec. Order No. 14,036, 86 C.F.R. 36987 (July 9, 2021).
1026	Letter from Janet Woodcock, Acting Comm'r of Food and Drug Admin., to Andrew Hirshfeld, Director of the U.S. Pat. and Trademark Off. (Sept. 10, 2021), available at https://www.fda.gov/media/152086/download?attachment (last visited January 23, 2024).

1027	U.S. Courts, Statistics and Reports, Table C-5, U.S. District Courts–Civil Federal Judicial Caseload Statistics (March 31, 2023), https://www.uscourts.gov/statistics/table/c-5/federal-judicial-caseload-statistics/2023/03/31 (last visited Jan. 22, 2024).
1028	Murphy, P. J., et al. "How Red Is a White Eye? Clinical Grading of Normal Conjunctival Hyperaemia." *Eye*, vol. 21, no. 5, 2006, pp. 633–638.
1029	Derick, R. J., et al. "Brimonidine Tartrate: A One-month Dose Response Study" *Ophthalmology*, vol. 104, no. 1, Jan. 1997, pp. 131–136.
1030	United States, Center for Drug Evaluation and Research, and Joanne Holmes. NDA 20-613 Alphagan™ (Brimonidine Ophthalmic Solution) 0.2% Sterile, vol. 1, U.S. Food and Drug Administration, 1985, pp. 1–286.
1031	U.S. Patent No. 11,833,245 (filed Jan. 30, 2023) (issued Dec. 5, 2023) ("'245 patent").
1032	David, R., et al. "Brimonidine in the Prevention of Intraocular Pressure Elevation Following Argon Laser Trabeculoplasty," *Archives of Ophthalmology*, vol. 111, No. 10, Oct. 1993, pp. 1387–1390
1033	Declaration of Robert Frederickson III in Support of Notice of Intent to Designate Provisionally Recognized PTAB Attorney as Back-Up Counsel under 37 C.F.R. § 42.10(c)
1034	U.S. Patent No. 6,562,873 (filed July 10, 2001) (issued May 13, 2003)
1035	Burke, J., and Schwartz, M., "Preclinical Evaluation of Brimonidine." Survey of Ophthalmology, vol. 41, no. 1, Nov. 1996, pp. S9–S18
1036	Declaration of Elaine H. Blais in Support of Notice of Intent to Designate Provisionally Recognized PTAB Attorney as Back-Up Counsel under 37 C.F.R. § 42.10(c)
1037	Not Used

1038	Declaration of Timothy J. Beavers in Support of Notice of Intent to Designate Provisionally Recognized PTAB Attorney as Back-Up Counsel Under 37 C.F.R. § 42.10(c)
1039	*In re Lumify*, No. 3:21-cv-16766-RK-RLS, D.I. 17 (D.N.J. Mar. 10, 2022)
1040	U.S. Pharmacopeia 28-National Formulary 23, 2005
1041	Conrad, J.M., et al., "Influence of Tonicity and pH on Lacrimation and Ocular Drug Availability", *Journal of the Parenteral Drug Association*, vol. 32, no. 4, July-Aug. 1978, pp. 149-161.
1042	Gonnering, R., et al., "The pH Tolerance of Rabbit and Human Corneal Endothelium," *Investigative Ophthalmology & Visual Science*, vol. 18, no. 4, pp. 373-390, Apr. 1979
1043	Naphcon A, Alcon Laboratories, Inc.
1044	Not Used
1045	Not Used
1046	Aieta, E.M. and Roberts, P.V., "The chemistry of oxo-chlorine compounds relevant to chlorine dioxide generation", *Water Chlorination: Chemistry, Environmental Impact and Health Effects*, vol. 1985, pp. 783–794
1047	Not Used
1048	Not Used
1049	OPHTHALMIC SOLUTIONS OF REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY 1380–1416 (19th ed., 1995)
1050	Langer S.Z. & Hicks, P.E., "Alpha-Adrenorecepter Subtypes in Blood Vessels: Physiology and Pharmacology," *Journal of Cardiovascular Pharmacology*, vol. 6, supp. 4, pp. S547-558, 1984
1051	Duka, et al., "Role of the Postsynaptic α_2-adrenergic Receptor Subtypes in Catecholamine-Induced Vasoconstriction," *General*

	Pharmacology: The Vascular System, vol. 34, no. 2, Feb. 2000, pp. 101-106
1052	Philipp M., Brede M., and Hein L., "Physiological significance of α_2-adrenergic receptor subtype diversity: one receptor is not enough", *American Journal of Physiology: Regulatory, Integrative and Comparative Physiology*, vol. 2, pp. R287–295, 2002
1053	Not Used
1054	Not Used
1055	Spector S.L. & Raizman M.B., Conjunctivitis Medicamentosa, *Journal of Allergy and Clinical Immunology*, vol. 94, no. 1, pp. 134–136, July 1994
1056	C.N.S. Soparkar et al., *Acute and Chronic Conjunctivitis Due to Over-the-Counter Ophthalmic Decongestants*, 115 ARCHIVES OF OPHTHALMOLOGY 34 (1997)
1057	STEDMAN'S MEDICAL DICTIONARY (28th Ed 2006)
1058	Not Used
1059	Not Used
1060	Not Used
1061	OPHTHALMIC SOLUTIONS OF REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY, Ch. 4, (20th ed., 2000)
1062	Aslanides I.M., et al., "Letter to the Editor," *Ophthalmology*, vol. 112, no. 12, Dec. 2005, pp. 2238.e8-2238.e9.
1063	Aslanides I.M., et al., "The Effect of Topical Apraclonidine on Subconjunctival Hemorrhage and Flap Adherence in LASIK Patients," *Journal of Refractive Surgery*, vol. 22, Jun. 2006, pp. 585-588
1064	Hong, S., et al., "Effect of Prophylactic Brimonidine Instillation on Bleeding During Strabismus Surgery in Adults," *American Journal of Ophthalmology*, vol. 144, no. 3, Sept. 2007 pp. 469-470

1065	NDC 4200220302, NDC 4200220335, Visine® Original Redness Relief Eye Drops (tetrahydrozoline) 0.05% (Visine Original Label)
1066	P. Agarwal, J. Craig, & I. D. Rupenthal, Review: Formulation Considerations for the Management of Dry Eye Disease, 13 PHARMACEUTICS 1 (2021).
1067	ALPHAGAN® (brimonidine tartrate ophthalmic solution) 0.5% Label (Dec. 2001), https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21262s6lbl.pdf (Alphagan Label 2001)
1068	ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.1% and 0.15%, (2006), https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021262s018lbl.pdf
1069	Not Used
1070	Not Used
1071	Naphcon A (naphazoline hydrochloride 0.025%, pheniramine maleate 0.3%), Alcon Laboratories (Naphcon A).
1072	Not Used
1073	D. N. Tzovolou, et al., *Capillary Electrophoretic Analysis of Brimonidine in Aqueous Humor of the Eye and Blood Sera and Relation of Levels with Intraocular Pressure*, 14 BIOMEDICAL CHROMATOGRAPHY 301 (2000).
1074	D. A. Lee, et. al, *The Effectiveness and Safety of Brimonidine as Mono-, Combination, or Replacement Therapy for Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: A Post Hoc Analysis of an Open-Label Community Trial*, 16 J. OCULAR PHARM. & THERAPEUTICS 3 (2000).
1075	Alphagan P (brimonidine tartrate ophthalmic solution) 0.1%, NDA No. 21770, Medical Review (2005).

1076–1111	Not Used
1112	T. Mundorf, et al., *A 3-Month Comparison of Efficacy and Safety of Brimonidine-Purite 0.15% and Brimonidine 0.2% in Patients with Glaucoma or Hypertension*, 19 J. OPHTHALMOLOGY & THERAPEUTICS 37 (2003).
1113–1129	Not Used
1130	Ö. Üretmen, et al., "Letter to the Editor," *Refractive Surgery*, vol. 19, 2013, p. 612.
1131	Desco, M.C., et al., "Effect of Prophylactic Brimonidine on Bleeding Complications After Cataract Surgery," *European Journal of Ophthalmology*, vol. 15 no. 2, 2005, pp. 228-232.
1132	Muñoz, G., et al., "Increased Risk for Flap Dislocation with Perioperative Brimonidine Use in Femtosecond Laser In Situ Keratomileusis," Journal of Cataract Refractive Surgery, vol. 35, 2009, pp. 1338–1342.
1133	Not Used
1134	K. Chuang, *Potential of Gene Editing and Induced Pluripotent Stem Cells (iPSCs) in Treatment of Retinal Diseases*, 90 Yale J. Bio. & Med. 635 (2017).
1135	K. Boyd and D. Turbert, *Eye Anatomy: Parts of the Eye and How We See,* AM. ACAD. OPHTHALMOLOGY, (Apr. 29, 2023), https://www.aao.org/eye-health/anatomy/parts-of-eye.
1136	*Scientists Discover Why Cornea is Transparent and Free of Blood Vessels, Allowing Vision*, SCHEPPENS EYE INSTITUTE, (July 17, 2006), https://www.eurekalert.org/news-releases/652982.
1137	K. Boyd, *What are Cataracts?*, AM. ACAD. OPHTHALMOLOGY, (Oct. 16, 2023), https://www.aao.org/eye-health/diseases/what-are-cataracts.

1138	H. Cronau, et al., *Diagnosis and Management of Red Eye in Primary Care*, 81 AM. FAM. PHYSICIAN 2 (2010).
1139	Not Used
1140	Not Used
1141	Not Used
1142	NDA020226, Naphcon A® (naphazoline hydrochloride) 0.025% and (pheniramine maleate) 0.3% ophthalmic solution
1143	NDA 019407, Visine® L.R. (oxymetazoline) 0.025%.
1144	Not Used
1145	Not Used
1146	Tal Raviv, *The Off-Label Use of Pharmaceuticals* (Nov. 23, 2002), https://talravivmd.com/the-off-label-use-of-pharmaceuticals/.
1147	Not Used
1148	H. Kaplan, *Anatomy and Function of the Eye*, *in* IMMUNE RESPONSE AND THE EYE, VOL. 92 (2d ed., 2007).
1149	M. Kuehn, et al., "Retinal Ganglion Cell Death in Glaucoma: Mechanisms and Neuroprotective Strategies," *Ophthalmology Clinic of North America*, vol. 18, Sept. 2005, pp. 383–395.
1150	R. Singh, et al., "Ocular redness – II: Progress in Development of Therapeutics for the Management of Conjunctival Hyperemia," *The Ocular Surface*, vol. 21, 2021, pp. 66–77.
1151	Wang, S., et al., "Therapeutic Efficacy of Topical Blockade of Substance P in Experimental Allergic Red Eye," *The Ocular Surface*, vol. 21, 2021, pp. 184–190.
1152	Utine, C.A., et al., "Radial Keratotomy for the Optical Rehabilitation of Mild to Moderate Keratoconus: More Than 5 Years' Experience," European Journal of Ophthalmology, vol. 16, no. 3, 2006, pp. 376–384.

1153	*Laser In Situ Keratomileusis (LASIK)*, NAT'L INST. HEALTH, NCBI BOOKSHELF, https://www.ncbi.nlm.nih.gov/books/NBK555970/ (last visited Jan. 5, 2024).
1154	J. Ruiz-Ederra, et al., *The Pig Eye As a Novel Model of Glaucoma*, 81 EXPERIMENTAL EYE RSCH. 561 (2005).
1155	Ventrella., D., et al., "The p-ERG Spatial Acuity in the Biomedical Pig Under Physiological Conditions," *Scientific Reports*, vol. 12, 2022, pp. 1–9.
1156	Crespo-Moral, M. et al., "Histological and Immunohistochemical Characterization of the Porcine Ocular Surface," *Plos One*, vol. 15, Jan. 13, 2020, pp. 1–17.
1157	R. Ruffolo, *Distribution and Function of Peripheral a-Adrenoceptors in the Cardiovascular System*, 22 PHARMACOLOGY BIOCHEM. & BEHAVIOR, 827 (1985).
1158	Z. P. Khan et al., *Alpha-2 and Imidazoline Receptor Agonists*, 54 ANAESTHESIA 146 (1999).
1159	S. Schonberg & T. Stokkermans, *Episcleritis*, *in* STATPEARLS (2023), https://www.ncbi.nlm.nih.gov/books/NBK534796/.
1160	M. B. Abelson & A. Vashishan, The Truth about Tachyphylaxis, Rev. Opthalmology (Mar. 16, 2006), https://www.reviewofophthalmology.com/article/the-truth-about-tachyphylaxis.
1161	K. Boyd, *What is Glaucoma? Symptoms, Causes, Diagnosis, Treatment,* AM. ACAD. OPHTHALMOLOGY, (Dec. 04, 2023), https://www.aao.org/eye-health/diseases/what-is-glaucoma (AAO Glaucoma).
1162	Not Used
1163	Not Used
1164	Not Used

1165	*Eyes: How They Work, Anatomy & Common Conditions*, CLEVELAND CLINIC, https://my.clevelandclinic.org/health/body/21823-eyes (last visited Jan. 21, 2024).
1166	*Nat'l Inst. Health, Ncbi Bookshelf*, THE OCULAR CIRCULATION, https://www.ncbi.nlm.nih.gov/books/NBK53329/ (last visited Jan. 5, 2024).

Dated: January 29, 2025

Respectfully submitted,

/Linnea P. Cipriano/

Linnea P. Cipriano
(Reg. No. 67,729)
Goodwin Procter LLP
620 Eighth Avenue
New York, NY 10018
Phone: (212) 813-8800
Cell: (443) 235-1739
Fax: (212) 937-2204
lcipriano@goodwinlaw.com

Counsel for Petitioners Dr. Reddy's Laboratories S.A. and Dr. Reddy's Laboratories, Inc.

CERTIFICATE OF SERVICE

I, Linnea P. Cipriano, certify that I caused to be served a true and correct copy of the foregoing **PETITIONERS' FOURTH UPDATED EXHIBIT LIST** by email, as follows:

Bryan Diner	bryan.diner@finnegan.com
Justin Hasford	justin.hasford@finnegan.com
Joshua Goldberg	joshua.goldberg@finnegan.com
Matthew Luneack	matthew.luneack@finnegan.com
Kassandra Officer	kassandra.officer@finnegan.com
Christina Yang	christina.yang@finnegan.com
Ryan V. McDonnell	ryan.mcdonnell@finnegan.com
M. David Weingarten	david.weingarten@finnegan.com
Ryan P. O'Quinn	ryan.o'quinn@finnegan.com

January 29, 2025

/Linnea P. Cipriano/

Linnea P. Cipriano
(Reg. No. 67,729)
Goodwin Procter LLP
620 Eighth Avenue
New York, NY 10018
Phone: (212) 813-8000
Fax: (212) 937-2204
lcipriano@goodwinlaw.com

Counsel for Petitioners